Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCOVER phase 3 PrEP study of emtricitabine/tenofovir alafenamide versus emtricitabine/tenofovir disoproxil fumarate
NL-OMON55726Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Descovy arm with Truvada arm (2 arms). Primary endpoint: Incidence of HIV-1 infection with minimum follow-up of 48 weeks and at least 50% of participants having 96 weeks follow-up. Started Apr 2017; status: completed.
02
Drugs
tenofovir alafenamideemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON55726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55726.